Skip to main content

Table 2 Clinicpathological associations of IGF-1 and IGFBP-1 expression levels and IGF-1/IGFBP-1

From: Higher IGFBP-1 to IGF-1 serum ratio predicts unfavourable survival in patients with nasopharyngeal carcinoma

Variables Cases IGFBP-1(ng/L) Significance IGF-1(ng/L) Significance IGFBP-1/IGF-1 Significance
(n) (Mean ± SD) (P)* (Mean ± SD) (P)* >1 ≤1 (P)*
 Gender
  Male 118 55.08 ± 41.66 0.966 88.26 ± 60.75 0.018* 38 80 0.202
  Female 24 55.93 ± 40.05 135.98 ± 88.78 4 20
 Age (y)
   < 46 73 47.18 ± 36.51 0.020* 103.65 ± 69.31 0.217 16 57 0.016*
   ≥ 46 69 63.85 ± 44.47 89.02 ± 66.48 28 41
 Tumor size
  T1 + T2 27 47.54 ± 36.71 0.260 87.09 ± 55.78 0.437 7 20 0.528
  T3 + T4 115 57.01 ± 42.18 100.71 ± 74.63 37 78
 Lymphoid nodal states
  N0-1 76 51.02 ± 41.80 0.156 96.69 ± 75.17 0.946 20 56 0.197
  N2-3 66 59.99 ± 40.41 99.79 ± 67.59 24 42
 Clinical Stage
  1 + 2 15 39.11 ± 37.45 0.101 99.42 ± 58.73 0.853 3 12 0.498
  3 + 4 127 57.11 ± 41.40 97.99 ± 73.02 41 86
 Local-regional relapse
  Yes 16 49.59 ± 39.68 0.537 117.07 ± 88.62 0.198 4 12 0.793
  No 126 55.94 ± 41.55 95.76 ± 69.08 40 86
 Metastasis
  Yes 4 43.16 ± 41.80 0.542 58.52 ± 27.71 0.263 1 3 0.775
  No 138 55.96 ± 41.20 97.42 ± 68.94 43 95
 WHO histological classification
  NKUC 131 57.05 ± 41.94 0.044* 98.25 ± 73.73 0.978 44 87 0.048*
  NKDC 11 38.18 ± 25.70 96.88 ± 36.79 0 11
 EA
   ≤ 1:10 53 44.34 ± 36.35 0.015* 104.31 ± 78.59 0.431 10 43 0.016*
   > 1:10 89 61.64 ± 42.79 94.51 ± 67.14 34 55
 VCA
   ≤ 1:40 14 57.45 ± 43.73 0.860 102.20 ± 50.26 0.736 2 12 0.263
   > 1:40 128 55.39 ± 41.05 95.68 ± 70.16 42 86
  1. *P < 0.05, as determined by Pearson’s Χ 2 test
\